Impact of Vedolizumab on Extraintestinal Manifestations in Inflammatory Bowel Disease: Results From a Descriptive, Retrospective, Real-world Study.
Uri KopylovBurisch JShomron Ben-HorinFiona BraeggerAlonso Fernández-NistalNuria LaraHenriette Sophie HeinrichStephan R VavrickaPublished in: Inflammatory bowel diseases (2023)
This real-world study showed resolution of all EIMs in up to one-fourth of patients with IBD and improvement in up to half of EIMs within 12 months of vedolizumab treatment. Overall, vedolizumab was effective on EIMs in patients with IBD and showed a good safety profile.